Subhashis Banerjee, M.D.

Senior Vice President, Clinical Development

Subhashis Banerjee, M.D., has served as our Senior Vice President of Clinical Development since July 2024. Dr. Banerjee is a trained immunologist and rheumatologist with over 25 years of drug development experience at large pharmaceutical companies. Dr. Banerjee most recently served as Vice President & Disease Area Head, Rheumatology and Dermatology at Bristol Myers Squibb (“BMS”) where he played a key role in the development strategy of immunology assets across multiple platforms for several immune-mediated diseases. During his tenure at BMS, Dr. Banerjee served as the global lead for mid- to late-stage clinical development of deucravacitinib, abatacept and clazakizumab for the treatment of a variety of immunological conditions. Previously, Dr. Banerjee served as a global clinical program lead at Eli Lilly on the clinical development of ixekizumab in rheumatoid arthritis, psoriasis, psoriatic arthritis and ankylosing spondylitis that led to marketing authorizations in the latter three indications. Earlier in his career, Dr. Banerjee supported preclinical and clinical development activities at Pfizer and AbbVie. Dr. Banerjee completed his medical schooling at Christian Medical College in Vellore, India, his residency in internal medicine at St. Vincent Hospital in Worcester, Massachusetts, and fellowships in Immunology at the Mayo Clinic, Rochester, MN and McGill University, Montreal.